Position for doctoral candidate (Dr. rer. nat. / PhD) in infectious disease immunology (m/f/x) for 3 years
Uniklinik Erlangen Stellenangebote →About the Institution and Research Environment
The Friedrich-Alexander-University (FAU) Erlangen-Nürnberg has been rated as one of the most innovative universities in Europe by Reuters or Times Higher Education. FAU and the University Hospital Erlangen (UKER) , which are located in the City of Erlangen in the North of Bavaria, Germany, carry out top-level research in immunology and have consistently ranked among the most successful German universities in attracting funding from the German Research Foundation ( Deutsche Forschungsgemeinschaft, DFG ) in the medical field of "Microbiology, Virology and Immunology". The FAU Profile Center Immunomedicine (FAU I-Med) unites more than 130 independent research groups from FAU, the UKER and the Max Planck Center for Physics and Medicine, which participate in numerous DFG-funded research consortia and provide a strong scientific environment. One of these DFG-funded research consortia is the Research Training Group (RTG; Graduiertenkolleg, GRK) 2740 "ImmunoMicroTope" , which has been headed by Prof. Christian Bogdan since 2022. It is run by 13 outstanding research group leaders of the University Hospital Erlangen and the FAU and maintains close cooperations with two laboratories at the Universities of Regensburg and Cologne. The RTG 2740 focuses on the in situ analysis of the tissue microenvironment, the micromilieu factors and the metabolites that determine the immune response against bacterial, parasitic and fungal pathogens. The overarching goal of the consortium is the characterization of the complex "immunomicrotope" during infections (Bogdan et al., Trends in Parasitology 2024 10.1016/j.pt.2024.07.013 ).
Project Description
Within the RTG2740 "ImmunoMicroTope ", Prof. Christian Bogdan offers a PhD position in his dynamic research team in the project B2 "Role of sex and microbiota for the curative effect of L-arginine in chronic cutaneous leishmaniasis due to Leishmania mexicana infection" .
Type 2 nitric oxide synthase (NOS2) converts the amino acid L-arginine in the presence of molecular oxygen into nitric oxide (NO), which exerts antimicrobial and immunoregulatory functions. In previous studies, Prof. Bogdan's group showed that NOS2 is essential for the type 1 T helper cell-dependent control of intracellular pathogens, including the protozoan parasite Leishmania . In contrast, the expression of arginase 1 correlated with the progression of disease, pathogen persistence and immunopathology. Moreover, the group observed that the non-healing, chronic course of cutaneous leishmaniasis in Leishmania mexicana- infected female mice was prevented and reversed by external application of L-arginine. Currently, it is unclear, whether this effect is sex-dependent and whether it is influenced by the cutaneous and/or intestinal microbiota. The project aims to address these questions and to provide new mechanistic insights into the therapeutic effect of L-arginine with the ultimate goal to establish a new host-targeted treatment for chronic cutaneous leishmaniasis.
For more information, please visit www.immunomicrotope.de and www.mikrobiologie.uk-erlangen.de/en/research/research-groups/research-group-of-prof-c-bogdan /.
General Conditions
- The program starts on July 1 st 2027
- The PhD position is available for initially 36 months
- Pay grade is determined according to the qualifications and personal requirements as defined by TV-L E13
Application Instructions
Please provide a single PDF file (last name_first name.pdf ) consisting of the following documents in English language:
- Completed application form (RTG 2740 Application form_PhD; www.immunomicrotope.de )
- Curriculum vitae
- Letter of motivation
- One-page summary each of the bachelor and master thesis
- Copies of the university entrance exam, Bachelor exam and Master exam
- Two letters of reference
- Other credentials and information relevant to the RTG2740 program
Please note that applications that do not fulfill these formal requirements, will not be considered.
Deadline for application is January 15, 2027.
The recruitment symposium will take place at the end of February 2027.